No­var­tis pe­ti­tions FDA to block 18 gener­ic com­peti­tors for its megablock­buster heart drug un­til 2024

No­var­tis is look­ing to milk one of its most prized pos­ses­sions a lit­tle while longer with­out any gener­ic com­pe­ti­tion, most­ly be­cause of a new­ly ap­proved use that the Big Phar­ma won ear­li­er this year for its megablock­buster heart drug En­tresto.

In ad­di­tion to bat­tling (and win­ning) lit­i­ga­tion last month to block a hand­ful of In­di­an gener­ics from en­ter­ing the mar­ket ear­ly along­side En­tresto, the com­pa­ny last week pe­ti­tioned the FDA to try to stop a to­tal of 18 En­tresto gener­ics from launch­ing be­fore 2024 at the ear­li­est.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA